Egypt’s drive to localise pharmaceutical manufacturing has attracted fresh regional investor interest, with Gulf companies expressing a desire to participate in the Arab API project, one of the country’s largest strategic investments in pharmaceutical raw materials.
Olfat Ghorab, Chairwoman of the Arab Company for Drug Industries and Medical Appliances (ACDIMA), said the company has received expressions of interest from Gulf investors seeking equity participation in the project. She added that ACDIMA remains open to bringing in additional strategic partners as construction progresses, with commercial operations targeted for 2028.
The Arab API complex is being developed in Ain Sokhna within the Suez Canal Economic Zone through a partnership between ACDIMA, EIPICO and the zone’s investment arm. The project, valued at approximately $150-165 million, will manufacture active pharmaceutical ingredients (APIs), inactive pharmaceutical raw materials, intermediates and specialty chemicals that currently rely heavily on imports.
The investment forms a cornerstone of Egypt’s broader pharmaceutical localisation strategy. Although the country manufactures the vast majority of its finished medicines domestically, industry estimates indicate that more than 90% of pharmaceutical raw materials are still imported, exposing manufacturers to foreign exchange volatility and global supply chain disruptions. The Arab API project seeks to reduce that dependence while strengthening Egypt’s pharmaceutical resilience and export competitiveness.
The facility will be built on a site covering nearly 97,000 square metres and is expected to become one of the first integrated API manufacturing complexes of its kind in Egypt and Africa. Initial production will focus on high-value active ingredients, including cephalosporin-related products, with future expansion planned into a wider range of pharmaceutical compounds required by domestic drug manufacturers.
For Gulf investors, the project offers exposure to one of the Middle East’s largest pharmaceutical markets while supporting regional healthcare security initiatives. Cross-border investment could also accelerate technology transfer, broaden financing options and strengthen regional pharmaceutical supply chains at a time when governments are increasingly prioritising local production of strategic medical products following recent global supply disruptions.
Beyond import substitution, Arab API is expected to improve Egypt’s trade balance by reducing the pharmaceutical sector’s foreign currency requirements while positioning the country as a regional supplier of pharmaceutical ingredients to African and Middle Eastern markets. Its location within SCZONE also provides direct access to international shipping routes and export infrastructure, reinforcing Egypt’s ambition to become a regional pharmaceutical manufacturing hub.
If completed on schedule in 2028, the project would represent a significant step in deepening Egypt’s pharmaceutical value chain—from finished drug production to upstream manufacturing of critical active ingredients—while attracting long-term regional capital into one of the country’s highest value-added industrial sectors.
Related news:
Can Cash-Flow Credit Scoring Reshape Lending in Egypt and the Middle East?
Saudi Arabia Leads GCC into Next Phase of Workforce Nationalisation
Read also:
Egypt Bets EGP 12bn on Vaccine Hub to Cut Imports and Expand Regional Reach
ACDIMA and EIPICO Anchor $165mn Arab API Project to Deepen Egypt’s Pharmaceutical
